Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

theoptionsplug Sep. 14 at 7:21 PM

$JNJ is once again trading within the marked support area Holding structure well against the $265 support level with the 50DMA acting as an additional support Looking for a break above $272 for call entry Put trigger under $261

0 · Reply

HydrogenH2 Sep. 14 at 6:31 PM

$JNJ Big boys are...

0 · Reply

DidYouReadThis Sep. 14 at 6:10 PM

What might be closest to your next entry point for $NVS ? $XLV $PILL $JNJ

1 · Reply

HydrogenH2 Sep. 14 at 4:38 PM

$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!

0 · Reply

notreload_ai Sep. 14 at 4:21 PM

$JNJ is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to $APO for about $20B. A deal could close in weeks—or J&J may spin it off. https://notreload.xyz/xy/jnj-in-talks-to-sell-depuy-synthes-to-apollo-for-20b/

0 · Reply

parcha Sep. 14 at 3:10 PM

Here are our top 10 things to watch in the stock market Monday $JNJ $DIA Johnson & Johnson is in talks with Apollo Global Management to sell its DePuy Synthes orthopedics business for around $20 billion. A sale would be a cleaner exit versus a planned separation. It’s a great way for J&J to become more focused on more profitable parts of medtech and its incredible line-up of drugs. https://www.cnbc.com/2026/09/14/here-are-our-top-10-things-to-watch-in-the-stock-market-monday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension

0 · Reply

OpenOutcrier Sep. 14 at 12:32 PM

$JNJ (+1.1% pre) J&J Is in Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion https://ooc.bz/l/114060

0 · Reply

JFais Sep. 14 at 12:20 PM

$JANX (NP) ~$100M EV, first patient dosed with PSMA CD28-costim bispecific (goal of enhancing durability of responses) @JoseRestonVA $JNJ moving its CD28 PSMA into phase 3 along with KLK2/CD3 re validation Will be interested to see how double-masked JANX014 shapes up vs $VIR (the former seems very far behind)

0 · Reply

Outcomes Sep. 14 at 12:14 PM

$IBRX $MRNA $MRK $PFE $JNJ .....'Turbo-cancers' PSS KNOWS. https://x.com/docBenk12/status/2099104918783098994?s=20

1 · Reply

peacewealth7447 Sep. 14 at 10:45 AM

$SLS $JNJ $BMY $CELG

0 · Reply

Johnson & Johnson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

Sep 13, 2026, 9:45 PM EDT - 17 hours ago

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Sep 12, 2026, 3:40 PM EDT - 1 day ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

APO

Sep 11, 2026, 6:47 PM EDT - 2 days ago

Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports

APO

Sep 10, 2026, 7:45 AM EDT - 4 days ago

Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses

Sep 9, 2026, 11:00 AM EDT - 5 days ago

Johnson & Johnson Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 8, 2026, 8:00 AM EDT - 6 days ago

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

Sep 2, 2026, 4:21 PM EDT - 11 days ago

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Aug 31, 2026, 5:08 PM EDT - 13 days ago

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Aug 27, 2026, 5:42 AM EDT - 18 days ago

China approves J&J's oral psoriasis pill, says drugmaker

Aug 24, 2026, 7:12 PM EDT - 20 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Aug 24, 2026, 6:33 PM EDT - 20 days ago

US FDA expands approval for J&J's drug for rare blood disorder

Aug 24, 2026, 12:20 PM EDT - 21 days ago

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Aug 13, 2026, 11:15 PM EDT - 4 weeks ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 6, 2026, 6:23 PM EDT - 5 weeks ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Aug 4, 2026, 4:05 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 8:45 AM EDT - 5 weeks ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: Investor update

Aug 2, 2026, 8:00 AM EDT - 6 weeks ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 6 weeks ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 6 weeks ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 6 weeks ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 6 weeks ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 6 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 6 weeks ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 6 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 6 weeks ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 6 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 6 weeks ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 6 weeks ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 6 weeks ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 7 weeks ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 7 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 7 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 7 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 7 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 7 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 2 months ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 2 months ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 2 months ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 2 months ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 months ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 months ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 2 months ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 2 months ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 2 months ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 2 months ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 2 months ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 2 months ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 2 months ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 2 months ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

theoptionsplug Sep. 14 at 7:21 PM

0 · Reply

HydrogenH2 Sep. 14 at 6:31 PM

$JNJ Big boys are...

0 · Reply

DidYouReadThis Sep. 14 at 6:10 PM

What might be closest to your next entry point for $NVS ? $XLV $PILL $JNJ

1 · Reply

HydrogenH2 Sep. 14 at 4:38 PM

$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!

0 · Reply

notreload_ai Sep. 14 at 4:21 PM

0 · Reply

parcha Sep. 14 at 3:10 PM

0 · Reply

OpenOutcrier Sep. 14 at 12:32 PM

$JNJ (+1.1% pre) J&J Is in Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion https://ooc.bz/l/114060

0 · Reply

JFais Sep. 14 at 12:20 PM

0 · Reply

Outcomes Sep. 14 at 12:14 PM

$IBRX $MRNA $MRK $PFE $JNJ .....'Turbo-cancers' PSS KNOWS. https://x.com/docBenk12/status/2099104918783098994?s=20

1 · Reply

peacewealth7447 Sep. 14 at 10:45 AM

$SLS $JNJ $BMY $CELG

0 · Reply

jamesmckevitt Sep. 14 at 10:44 AM

$SLS just a quick reminder: Michael Frascello of $JNJ has been studying GPS/REGAL for 1.5 years called it a “game changer” in AML. Katherine Bach Kalin on the board of SLS was part of $BMY huge 74b purchase of $CELG and purchase a huge amount of shares 9 months ago. Michael Anglestein of AstraZenica also stated GPS was a game changer for AML patients. Not one of the board have sold a single share either, I’m down; but not out!

0 · Reply

focafoca99 Sep. 14 at 6:14 AM

$JNJ posted longest reported median overall survival in EGFR exon 20 insertion NSCLC with RYBREVANT plus chemo https://www.rapidticker.com/news/jnj-johnson-johnsons-rybrevant-amivantamab-vmjw-d762b0

0 · Reply

StockBraker Sep. 13 at 2:38 PM

$JNJ https://seekingalpha.com/news/4642256-apollo-in-talks-to-acquire-j-and-j-s-orthopedics-unit-bloomberg

0 · Reply

TalkMarkets Sep. 13 at 12:57 PM

3 Top Dividend Aristocrats To Own Near All-Time Highs $JNJ $KO $XOM https://talkmarkets.com/article/3-top-dividend-aristocrats-to-own-near-all-time-highs-1789304223

0 · Reply

Gebinator Sep. 12 at 10:56 PM

$SLS $JNJ $MRK $ABBV September is recognized worldwide as Blood Cancer Awareness Month and Leukemia and Lymphoma Awareness Month, which includes bringing attention to AML. This month, as we reve in the stock price volatility and FOMO frenzy in an anticipation of REGAL '80th event', may we also take a few moments to remember the 80th 'event' is the end of someone's human life? Assuming REGAL success -- I hope the IDMC / FDA / Company would honor the life of this 'event' and all 79 events before, by expediting REGAL FA and the Accelerated Approval process. I'm sure all 80 events would want it that way.

2 · Reply

dewmoore Sep. 12 at 10:42 PM

$SLS $JNJ just go ahead and end this for everyone -- simply use that $20B + another $20B and let's end the drama and get $SLS GPS to market! https://www.wsj.com/business/deals/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billion-3018cc4e

3 · Reply

StocktwitsNews Sep. 11 at 11:47 PM

JNJ Stock Edges Up After-Hours On Apollo’s $20B Orthopedics Talks $JNJ $VTI $VOO https://stocktwits.com/news/equity/markets/jnj-stock-edges-up-after-hours-on-apollo-s-20-b-orthopedics-talks/cZtXy60RBbk

0 · Reply

Waliansari Sep. 11 at 10:49 PM

$JNJ

0 · Reply

Equibles Sep. 11 at 8:26 PM

$JNJ This one turned up on Equibles. Johnson & Johnson EVP, WW Chair, MedTech Schmid Timothy reported selling 22,527 JNJ shares on September 2, 2026, worth about $6.19 million, in a non-derivative Form 4.

0 · Reply

Techdamentals Sep. 11 at 7:42 PM

$JNJ Same rate environment that pressures high-multiple tech barely touches this one. Most of the value arrives near term. Techdamentals IV Calculator 👇 https://techdamentals.com/v/JNJ Educational, not advice.

0 · Reply

Outcomes Sep. 11 at 1:15 PM

$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD. 'Turbo-cancers', etc. PSS KNOWS. SAVE THE CHILDREN. MAHA. https://x.com/MaryanneDemasi/status/2098375021320417588?s=20

1 · Reply

Market Cap	640.02B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.45
Forward PE	22.95
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	1,994,432
Avg Vol	7,102,680
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	3%
Beta	0.24
Analysts	Strong Sell
Price Target	$280.04